An ROC curve analysis was performed to calculate the AUC for serum TNFR2 to determine the prognostic ability to predict progression to stage 4 CKD on follow-up. The ROC curve illustrated the prognostic utility of serum TNFR2 in predicting stage 4 CKD, with an AUC of 0.683 (95% CI: 0.534 - 0.831, p = 0.032) and a sensitivity of 68% and specificity of 64%, as shown in Figure 3D. The gene discussed is TNFRSF1B; the disease is chronic kidney disease.